Ob/Gyn Updated

First live birth after deceased donor uterine transplant takes place at the Cleveland clinic

noreply@blogger.com ( Anjali Vyas) — Wed, 10 Jul 2019 05:45:00 +0000

This June 18, 2019 photo provided by the Cleveland Clinic

Cleveland Clinic in Ohio becomes the first hospital in North America to deliver a baby born out of uterus that was transplanted after the donor was deceased.

The mother, who is in her mid-30s, is part of a groundbreaking research trial involving 10 women with uterine factor infertility, who are all destined to receive uterus from deceased donors. Since the start of the trial, the team has performed 5 uterine transplants, of which 3 were successful, including the one which resulted in a live birth. Two other women are waiting for embryo transfer.

The baby was delivered “en caul,” meaning the amniotic sac remained intact until after the delivery. This is an extremely rare but safe occurrence and happened spontaneously with this delivery, adding to the special occasion. The woman whose identity was not disclosed chose to remove the uterus after delivering the baby.

This is the second birth from a uterus from a deceased donor, the first occurred in 2017 in a Brazilian trial involving a 32-year-old woman born without a womb who received a uterine transplant from a 45-year-old woman who'd died of a stroke.

Here is the video from Cleveland Clinic

First medical device developed to filter blood to treat preeclampsia

noreply@blogger.com ( Anjali Vyas) — Wed, 10 Jul 2019 05:04:00 +0000

courtesy: APT

The U.S. Food and Drug Administration (FDA) granted a Breakthrough Device Designation for the Advanced Prenatal Therapeutics, Inc. (APT) Targeted Apheresis Column for Preeclampsia (TAC-PE) in the treatment of preeclampsia.

Currently, the therapeutic options for preeclampsia are limited and include bed rest, anti-hypertensive medications and induction of preterm labor if needed.

The TAC-PE column is an apheresis device that works like kidney dialysis in selectively removing the harmful substances from the blood. While the exact cause of preeclampsia is not known, several biomarkers have been identified that are responsible for life-threatening preeclampsia symptoms like kidney and liver dysfunction and high blood pressure.

The apheresis procedure resembles voluntary blood donation. The woman’s blood is pumped through the apheresis machine to separate it into plasma and blood cells. The plasma then passes through the TAC-PE device, where the toxic substances are captured. The toxin-free plasma is mixed with the cells and returned to the patient.

APT first therapeutic target is soluble fms-like tyrosine kinase-1 (sFlt-1). The circulating sFlt-1is made by the placenta and antagonizes the action of Vascular endothelial growth factor (VEGF), that triggers new vessel formation and vasodilatation in normal pregnancies. Pre-eclampsia occurs when the relative functional activity sFlt-1 exceeds that of VEGF resulting in vasoconstriction in important organs like kidney, liver, and brain (the organs most affected by preeclampsia).

Removal of sFlt-1 from blood helps to restore the vascular homeostasis by alleviating the endothelial dysfunction. This eliminates the need for premature termination of pregnancy, helps stabilize the mother and baby to let the pregnancy proceed naturally to term.

“We were navigating virtually uncharted waters in 2005 when we first proposed that preeclampsia could be treated using an apheresis column to remove pathogenic factors such as sFlt-1,” said Dr. James Smith, President/CEO of APT. “Now that we are preparing for initial clinical studies, we are very pleased that the Breakthrough Designation will help provide a clear and efficient pathway to market.”

APT is a Laguna Hills, California based company involved in developing an effective treatment that will safely prolong pregnancy, allowing babies more time to develop in the womb in patients with preeclampsia.

TAC-PE: TARGETED APHERESIS COLUMN FORPREECLAMPSIA

Advanced Prenatal Therapeutics PressRelease…

Here is a video from APT

FDA approves a new drug for increasing libido in premenopausal women

noreply@blogger.com ( Anjali Vyas) — Sun, 30 Jun 2019 21:23:00 +0000

Courtesy: AMAG Pharmaceuticals

The US Food and Drug Administration (FDA) recently approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

Vyleesi, a melanocortin receptor agonist that comes as autoinjector, joins flibanserin(Addyi, Sprout Pharmaceuticals) as the class of drugs approved by the FDA for the treatment of acquired HSDD. Flibanserin is Serotonin 5-HT-Receptor Agonists and is taken orally.

HSDD is the most commonly prevalent female sexual dysfunction and is largely under-recognized and undertreated. It is believed that approximately 9% of all premenopausal women in the United States experience it but less than half of these patients seek help or initiate discussions with physicians.

“Women with HSDD often avoid situations that could lead to intimacy, the impact of which goes far beyond the bedroom and can often result in anxiety, loss of vitality, self-esteem issues and relationship stress. It is important that women suffering from this condition have a choice of treatment options available to them,” quote Anita H. Clayton, M.D., Chair, Department of Psychiatry & Neurobehavioral Sciences, University of Virginia School of Medicine, VA in an AMAG Pharma news release.

The upside of bremelanotide is women need to use it as required as opposed to flibanserin which must be consumed daily. The drug is dispensed as prefilled autoinjector pen which has to be self-administered by the woman into her abdomen or thigh at least 45 minutes before anticipated sexual activity and can be taken at any time of day.

Courtesy: AMAG Pharmaceuticals

Patients should not use more than one dose within 24 hours or more than eight doses per month. Patients should discontinue treatment after eight weeks if they do not report an improvement in sexual desire and associated distress.

While the exact mechanism of action is still unknown, the drug is believed to act on the melanocortin receptors in the central nervous system that are thought to be associated with sexual function.

The FDA approval of Vyleesi is based upon data from approximately 1,247 women in two pivotal (NCT02333071 and NCT02338960), replicate, double-blind placebo-controlled Phase 3 trials (RECONNECT). Most patients used the drug 2-3 times a month with no more than once a week.

Vyleesi does not enhance sexual performance, but there was a statistically significant increase in desire and decrease in distress at the time of intimacy. Women in both the trials didn’t experience any problem with the autoinjector.

The most common side effects of Vyleesi are nausea and vomiting, flushing, injection site reactions, and headache. An increase in blood pressure was also noted, which usually resolved in 12 hours. Hence, Vyleesi is contraindicated in patients at high risk of cardiovascular disease and those with high-blood pressure.

Vyleesi is not indicated for the treatment of HSDD in postmenopausal women or in men. AMAG is expected to make Vyleesi commercially available in September 2019 through select specialty pharmacies.

FDA press release

AMAG Pharmanews release

FDA approves first ever diagnostic test for Mycoplasma genitalium

noreply@blogger.com ( Anjali Vyas) — Mon, 04 Feb 2019 21:50:00 +0000

The US Food and Drug Administration (FDA) approved the first-ever diagnostic test to aid in the diagnosis of sexually transmitted Mycoplasma genitalium infection. The Aptima Assay from Hologic Inc, is the only FDA-approved test to detect this under-recognized but increasingly common sexually transmitted infection (STI).

First discovered in the early 1980s, M. genitalium was listed as an emerging public health threat by the U.S. Centers for Disease Control and Prevention (CDC) in 2015. Currently, it is responsible for causing approximately 15 to 30 percent of persistent or recurrent urethritis cases in men in the United States and 10 to 30 percent of cervicitis cases in women.

This slow-growing pathogen is difficult to detect by traditional laboratory testing methods. In the absence of FDA approved diagnostic test, the STI is often misdiagnosed and treated with wrong antibiotics resulting in persisting infection and widespread transmission.

“Although Mycoplasma genitalium is typically more common than gonorrhea, there is very little public awareness of this rising sexually transmitted infection, which can cause serious and potentially devastating health problems,” said Damon Getman, Ph.D., senior principal research scientist and director of research at Hologic in a press release.

The Aptima Assay is a nucleic acid amplification test, which detects M. genitalium in urine samples and urethral, penile meatal, endocervical or vaginal swab collected in a clinical setting, such as a doctor’s office or clinic.

In the clinical study involving 11,774 samples, the Aptima test correctly identified M. gen. in approximately 90 percent of vaginal, male urethral, male urine and penile samples. It also correctly identified the presence of the pathogen in female urine and endocervical samples 77.8 percent and 81.5 percent of the time.

The test also has a high negative predictive value and correctly identified the negative samples 97.8 to 99.6 percent of the time. Vaginal swabs are the preferred samples to perform the test, but urine samples can be used as alternative sample types.

The assay is immediately available at clinical laboratories, physicians and healthcare providers can immediately order the tests by reaching out to the labs. Hologic further anticipates that most insurance plans will cover the testing for M. genitalium.

The Aptima Mycoplasma genitalium Assay was reviewed through the de novo premarket pathway, a regulatory pathway for some low- to moderate-risk devices of a new type. The FDA exercises special controls over the individual tests approved by the de novo premarket route to ensure the safety and effectiveness of the tests.

The newest M. genitalium assay joins the comprehensive list of men and women’s health assays by Hologic that include sexual and cervical health, and virology testing.

FDA press release

Hologic press release

Ob/Gyn Updated Facebook page

Delaying newborn's first bath increases exclusive breastfeeding rate

noreply@blogger.com ( Anjali Vyas) — Thu, 31 Jan 2019 01:06:00 +0000

A new Cleveland Clinic study has shown that delaying the first baby bath after delivery increases the breastfeeding rate by 8%, with 49% increased odds of exclusive breastfeeding while in the hospital. These mothers also continued breastfeeding their babies after discharge from the hospital. The odds further increased to 60% if the mother had a vaginal birth versus cesarean birth.

The researchers at Cleveland clinic looked at data from about 1000 mother-newborn couplets in this retrospective, two-group, pre- and postintervention design study. In the intervention group, the first bath was delayed for at least 12 hours vs. following the routine hospital practice of bathing the baby in a couple of hours after birth in the control group.

The demographics were comparable in both the groups. After multivariate regression analysis, it was observed that there was a significant increase in exclusively breastfeeding rates in the study group in whom the bath was delayed for 12 hours.

Why delaying the bath increases the breastfeeding rate is unclear, but researchers behind the study speculate that similarity between the smell of breast and amniotic fluid may better help the baby to latch.

The study adds support to the initiative of establishing immediate skin-to-skin (STS) contact between mother and baby. STS contact has been promoted internationally through the Baby-Friendly Hospital Initiative (BFHI) as a means to improve breastfeeding initiation, exclusivity, and duration after hospital discharge.

“Human touch is vital to the parent and the baby. You need to have that human touch. I think that by not washing the baby (so soon), encouraging skin-to-skin contact and breastfeeding, you’re improving that human touch. So, you’re now looking at a long-term health benefit,” explains Heather DiCioccio, DNP, RNC-MNN, who led the study. The study was published ahead of print in Journal for Obstetrics, Gynecologic, and Neonatal Nursing.

Those babies who received bath after 12 hours were also able to maintain their temperature better as compared to early bathers.

Research has also shown that increased rates of breastfeeding have a wealth of benefits for mother and child in years to come. Risk of childhood and maternal illnesses decrease considerably potentially decreasing the lifetime healthcare costs.

Here is a beautiful video by Cleveland Clinic explaining the findings

Press release

Full Text

Ob/Gyn Updated Facebook page

NAMS video series 2019: Understanding the etiology and mechanism of vasomotor symptoms

noreply@blogger.com ( Anjali Vyas) — Wed, 23 Jan 2019 23:11:00 +0000

The North American Menopause Society (NAMS) regularly posts comprehensive videos for clinicians about important midlife health topics. All interviews in the series are hosted by NAMS Board of Trustees Member and Past-President Dr. Marla Shapiro, a Canadian physician who led this exciting initiative. Dr. Shapiro is also a medical consultant for CTV News.

In this first video of 2019, Dr. Rebecca Thurston, Director of the Women’s Biobehavioral Health Laboratory and Professor of Psychiatry, Psychology, Epidemiology, and Clinical and Translational Science at the University of Pittsburgh throws some light on the why and how about vasomotor symptoms (VMS).

The natural history of vasomotor symptoms is still evolving. It is estimated that about 75% of women experiencing menopause will have hot flashes. A substantial number of women seen in everyday gynecological practice or specialty menopause clinic report VMS well past the age of 60 and some well into the 80s.

Hot flashes considerably reduce the quality of life and hamper the day to day activities. Prevalence of VMS is generally associated with increased risk of CVD due to endothelial dysfunction. Hence, women with VMS could be screened for CVD risk factor and offered lifestyle modifications and frequent screening for early diagnosis and prevention.

Ob/Gyn Updated Facebook page

Osteoporosis drug Romosozumab receives marketing approval in Japan

noreply@blogger.com ( Anjali Vyas) — Fri, 18 Jan 2019 01:49:00 +0000

Monoclonal antibody romosozumab gains first-ever marketing approval in Japan for the treatment of osteoporosis in patients at high risk of fracture announced Amgen and UCB in a joint press release. The drug will be known as Evenity in Japan and would be developed by Amgen Astellas BioPharma K.K.–a joint venture between Amgen and Astellas Pharma Inc., headquartered in Tokyo.

Romosozumab has a dual effect on the bone– it works by binding and inhibiting the activity of the protein sclerostin which increases bone formation and decreases bone breakdown.

Japanese people have the longest life expectancy in the world and with that comes the burden of osteoporotic fractures. In Japan, the osteoporotic fracture is the leading cause of disability that requires long term nursing home care.

"The approval of EVENITY in Japan is a significant milestone that reinforces our commitment to bringing effective treatments to the millions of patients who suffer from osteoporosis," said David M. Reese, M.D., executive vice president of Research and Development at Amgen in a news release.

"A patient with a prior osteoporotic fracture is twice as likely to suffer another fracture if left undiagnosed and without appropriate treatment. With this approval, physicians in Japan now have a new medicine to help patients reduce their risk of fracture."

The approval is based on results of two phase 3 clinical trials– FRAME and BRIDGE. The FRActure study in postmenopausal woMen with ostEoporosis (FRAME), included 7,180 postmenopausal women with osteoporosis. The women received romosozumab 210 mg s.c. or placebo once monthly for 12 months, followed by denosumab 60 mg s.c. once every 6 months in both groups for 12 months. The drug significantly increased spine and hip BMD and reduced vertebral and clinical fracture risk.

The BRIDGE study (placeBo-contRolled study evaluating the efficacy anD safety of romosozumab in treatinG mEn with osteoporosis) involved 245 men with osteoporosis (163 romosozumab, 82 placebo) randomized 2:1 to receive either 210 mg romosozumab or placebo subcutaneously once monthly for 12 months. Men on Romosozumab showed a significant bone mineral density (BMD) gains at the lumbar spine, total hip and femoral neck compared to placebo at six and 12 months.

The approval is also significant because FDA rejected Amgen’s initial marketing application for Romosozumab in the US because of cardiovascular side effects of the drug in ARCH trial. The drug is also under regulatory review in Europe.

The Japanese Pharmaceuticals and Medical Devices Agency undertook a thorough review of the safety profile of EVENITY, including the cardiovascular safety findings in the ARCH trial.

Toshio Matsumoto, M.D., Ph.D., emeritus professor of Tokushima University and the advisor of the university's Fujii Memorial Institute of Medical Sciences said in the press release, "Physicians have been waiting for a new therapeutic option. I have great hope that the approval of EVENITY will help reduce the fracture risk for patients in Japan."

"Patients with a prior fracture face the risk of having another fracture and particularly stand to benefit from the option of a new bone-forming agent," he further added.

Meanwhile, During the second review cycle, the US Food and Drug Administration (FDA) Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) recently voted in favor of approving Amgen and UCB’s romosozumab (EVENITY) In the US for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The committee indicated that the drug benefits for treatment of postmenopausal osteoporosis outweigh its risk.

Press release

Ultrasound revisited–Personalized imaging anywhere, anytime and by anyone

noreply@blogger.com ( Anjali Vyas) — Wed, 16 Jan 2019 00:25:00 +0000

Will personal ultrasound scanners be readily available and accessible as home glucose or blood pressure monitors? It is possible right now with the Butterfly iQ handheld ultrasound wand and an iPhone– recently showcased at the CES 2019 at Las Vegas.

The new FDA cleared, pocket-sized ultrasound ushers in a new era of medical imaging at a fraction of the cost of large in-office machines. Currently, the FDA clearance covers 13 clinical applications, the broadest ever for a single ultrasound transducer.

The technology is currently only available for trained medical professionals, but shortly it may be possible to get an ultrasound examination without leaving the comforts of the home. The Butterfly team is beta testing software that can guide patients to capture the scans correctly and share it with respective healthcare providers in real time.

iQ is equipped with the latest Ultrasound-on-Chip technology™, where a single silicon chip replaces the piezo-electric crystals of the traditional ultrasound machines. The 2D array of 9000 programmable micro-machined sensors eliminate the need of linear, curved or phased probes for different parts of body. A single probe can be used to image different systems of the body including Ob/gyn, cardiology, musculoskeletal, and many others. Just slather the probe with gel, and it is possible to switch between different examinations easily.

The probe is compatible with many iPhone models including Apple iOS 11.0 or newer. The built-in battery is optimized for 2 hours continuous scanning or 10-hour shift and can be easily recharged by placing it on the wireless charging base. The iQ device is sleek and housed in an anodized aluminum body to withstand fall or temperature variations,

All the data and images are stored on Butterfly cloud and can be accessed from anywhere at any time. HTTPS, TLS 1.2 and AES 256-bit encryption and monitoring ensure that patient’s scan and personal is protected while at rest and at the time of sharing with the colleagues, peer or health providers. Images can be shared as easily as texting. Just open the image, tag the person and send it as a message.

The Ultrasound comes with deep learning-based artificial intelligence applications tightly coupled to the hardware and helps clinicians with both image acquisition and interpretation. As more and more clinicians use the system, the data acquired to improve the neural network models. This, in turn, will enable the less skilled personnel to capture images correctly.

Priced under $2,000, the Butterfly iQ is currently available for purchase in the US, but it can be reserved for purchase in other countries.

Here is a video about working of Butterfly iQ

Product page

Reserve your iQ here

Novel implantable shock absorbing device to relieve pain and delay progression of knee osteoarthritis

noreply@blogger.com ( Anjali Vyas) — Thu, 10 Jan 2019 00:31:00 +0000

Patients with osteoarthritis (OA) could now delay or avoid knee replacement surgery with the help of a new shock absorbing device that can be implanted alongside the knee joint. The Wexner Medical Center at the Ohio State University becomes the first center in US to implant the CalypsoKnee System to address the pain of the osteoarthritic knee.

Developed by Moximed, a company based in Fremont, California, a prospective, multicentric clinical trial is underway to look at the ability of the device to extend the life of knee joint and enable the patients to lead a pain-free, comfortable life.

The system is put in place under the skin, alongside the medial side of the affected knee through a small incision. The ligaments and bones forming the knee joints are preserved, keeping options open for any future surgical interventions.

With more than 700,000 knee replacement surgeries performed in the U.S. every year, the Calypso Knee System could reverse the trend and delay or avoid the replacement surgery.

Dr. David Flanigan, an orthopedic surgeon at The Ohio State University Wexner Medical Center who performed the surgery said in a news release, “ It works like a shock absorber to take pressure off the inside of the knee while creating a cushion similar to what cartilage provides in a healthy joint. The hope is that it increases joint functionality, reduces pain and delays a total knee arthroplasty for years or even decades.”

If found successful, it will soon be available as an option to knee replacement for osteoarthritic patients across the country.

The video shows how the system works in our body

Here is a video with more information on the first patient fitted with the system

Product page

Ohio state university press release

Minimally invasive transcervical radiofrequency ablation shows promising results for uterine fibroids

noreply@blogger.com ( Anjali Vyas) — Wed, 09 Jan 2019 00:43:00 +0000

Ultrasound-guided transcervical radiofrequency ablation provides an effective, safe and minimally invasive alternative for the treatment of symptomatic uterine fibroids suggests the results of pivotal IDE trial published in the January issue of Obstetrics & Gynecology.

The prospective, longitudinal, multicenter Sonography-Guided Transcervical Fibroid Ablation (SONATA) trial evaluated Gynesonics's investigational Sonata system in the treatment of heavy menstrual bleeding (HMB) because of uterine leiomyomata.

The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure to treat symptomatic uterine fibroids.

The trial enrolled 147 premenopausal women between age 25-50 years with HMB for at least three months, across 22 centers in the United States and Mexico. The size and number of fibroids varied between 1 to 5 cm diameters and 1-10 fibroids per woman respectively.

All women were followed for 12 months and results assessed in terms of relief from heavy menstrual blood loss, device-related complications, and surgical intervention rate.

Scott Chudnoff, Chief of OB/GYN at Stamford Hospital, Stamford CT a principal investigator in the SONATA trial, said in a press release, “The actual results achieved in the SONATA trial far exceed the required thresholds established by the FDA for the co-primary endpoints of reduction in menstrual bleeding and freedom from surgical reintervention for bleeding. These results, along with the impressive levels of patient satisfaction and rapid return to normal activity achieved, clearly demonstrate the potential for Sonata as a first line treatment for symptomatic fibroids.”

At the end of follow-up period of 12 months, 99% of patients did not require any additional surgical intervention for controlling HMB, 94% of patients reported relief from substantial blood loss with 60% reporting a 50% reduction in the amount of blood loss.

There was minimal surgical downtime with half of them returning to regular activity the next day of surgery, and 97% were satisfied with the procedure. No device-related complications were reported.

Procedure-related adverse events reported include fibroid sloughing (30.6%), cramping or pain (7.5%), leukorrhea (6.1%), and uncomplicated genitourinary infections (4.8%).

The results of the study earned FDA clearance for the SONATA system in August 2018. The results were also consistent with the previously published FAST-EU trial. Chris Owens, President and CEO stated.

“Considering these two prospective, multicenter trials were comprised of several disparate patient populations across two continents and performed by a broad range of physician operators across various healthcare delivery systems, and clinical settings, the consistency of these results is remarkable. The reproducible results highlight the robustness of the Sonata platform design and its potential to become a new standard of care for fibroid treatment.”

Gynesonics funded the study, and lead author have received travel and lodging expenses and honoraria for speaking for Gynesonics.

Here is a video showing SONATA system overview

Abstract

Gynesonics Press Release

Ob/Gyn Updated Facebook page

Media courtesy: Gynesonics

New café in Tokyo houses all robot staff operated remotely by people with disabilities

noreply@blogger.com ( Anjali Vyas) — Tue, 08 Jan 2019 02:01:00 +0000

A new café recently opened in Tokyo is entirely staffed by robots controlled by disabled people remotely. Contrary to the negative side of automation, the café creates jobs for people with severe debilitating conditions like amyotrophic lateral sclerosis (ALS) and spinal cord injuries.

Named Diverse Avatar Working Network) ver.β (DAWN), the café was launched as a joint project between Ory Lab, which develops the robots, Nippon Foundation, and ANA Holdings. The robots serving in the café is OriHime-D–a 4-foot-tall, altogether robot that moves, look around, handles objects, and speak with patrons at Tokyo’s Café. It has a built-in camera, a microphone and a speaker and can remotely control from a smartphone or a PC using the Internet.

Joysticks, blow tubes, or just the movements of the eye easily control the robots to serve coffee and intermingle with the customers. The disabled person or other people who cannot get out of home can earn money comfortably working from home or nursing home.

Currently, there is a staff of 10 people all working remotely from home and get paid 1,000 yen (US$8.80) an hour (a standard wage for part-time work in Japan).

The café was a pilot project for a temporary period and was funded by crowdfunding drive which doubled its funding goal. If the funds are made available on a regular basis, it is hoped that a full-fledged Dawn will open in 2020.

Here is a promo video to give a glimpse of how the concept works

A more realistic demonstration of how a operator controls the robot

A video of the opening ceremony

Product page

Via SoraNews

Ob/Gyn Updated Facebook page

What is the most effective uterotonic agent to prevent PPH?

noreply@blogger.com ( Anjali Vyas) — Thu, 03 Jan 2019 00:25:00 +0000

Postpartum hemorrhage (PPH) is responsible for more than 25% of all maternal death around the world and is the leading cause of maternal mortality in low resource settings. It affects 5% of all women during labor and leads to substantial morbidity because of compromised maternal blood volume.

Use of uterotonics during the third stage of labor could avoid a majority of complications due to PPH. WHO recently published updated guidance on uterotonics for the prevention of PPH, after which the Cochrane Review published the results of a network meta‐analysis to identify the most effective uterotonic agent.

The network meta‐analysis included 196 trials involving 135,559 women, with the majority of women having vaginal births (71.5%, 140/196) in a hospital setting (95.4%, 187/196).

The WHO recommendations and results of the Cochrane analysis suggest:

To effectively prevent PPH, only one of the following uterotonics should be used: Oxytocin, Carbetocin, Misoprostol, Ergometrine/methylergometrine, Oxytocin, and ergometrine fixed-dose combination.

Oxytocin (10 IU, IM/IV) is the standard recommended drug of choice for prevention of PPH in all cases. The drug has minimum side effects and is cost effective too. The main problem with Oxytocin is it requires refrigeration and rapidly loses its potency if stored at room temperature.

The use of carbetocin (100 µg, IM/IV) is also recommended for the prevention of PPH for all births if cost is not the limiting factor. It is also not readily available everywhere.

Misoprostol, injectable prostaglandins, and ergometrine have no additional benefits compared with oxytocin. Misoprostol causes more undesirable effects than oxytocin (including nausea, vomiting, shivering, fever, and diarrhea).

Combination therapy involving ergometrine plus oxytocin combination (Syntometrine ®), misoprostol plus oxytocin combination and carbetocin have the additional desirable effects compared with oxytocin and can be used if oxytocin is unavailable. However, there is always a risk of undesirable side effects as compared to oxytocin. Injectable prostaglandins (carboprost or sulprostone) are not recommended for the prevention of PPH.

Misoprostol and oxytocin are not available in fixed-dose combination and require different routes of administration so its use in routine clinical settings may not be very feasible as compared to using them alone.

If using ergometrine (alone or in combination), it is important to rule out hypertensive disorders and cardiovascular diseases.

In low resource settings and non-availability of skilled healthcare personnel, misoprostol (400 µg or 600 µg) can be administered orally by the community or lay health workers.

WHO recommendations Uterotonics for the prevention of postpartum haemorrhage

Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis

Ob/Gyn Updated Facebook page

FDA clears first ever test to analyze the nutrients in Human Breast Milk

noreply@blogger.com ( Anjali Vyas) — Tue, 01 Jan 2019 00:59:00 +0000

The U.S. Food and Drug Administration recently permitted marketing of a diagnostic test that analyzes nutrients in breast milk. The test will help healthcare providers in managing the specific nutritional needs of newborns and young infants at risk for growth failure due to prematurity or other medical conditions.

Developed and marketed by a Swedish company Miris, the Miris HMA - Human Milk Analyzer reports the fats, carbohydrates, proteins, and energy content of the milk within 60 seconds using 1-3 cc of the milk.

“For the first time, doctors have access to a test to help analyze the nutrients in breast milk. While this test is not for everyone, it has the potential to aid parents and healthcare providers, mainly in a hospital setting, in better assessing the nutrient needs of certain babies who are not growing as expected,” said Courtney Lias, Ph.D. director of the Division of Chemistry and Toxicology Devices in the FDA’s Center for Devices and Radiological Health in a press release.

“Breast milk provides many health benefits to infants, and for many babies, it can meet their early nutritional needs. But some infants — including those who may be born preterm or have certain health conditions — may need additional nutrients in order to support their optimal growth,” she further added.

“Knowing the macronutrient content of the breast milk may help the health care team and parents make informed decisions on how to fortify the breast milk based on the individual needs of the infant,” explains FDA in the recent press release.

The Miris Human Milk Analyzer can be purchased only through prescription and is for use by trained personnel at clinical laboratories. The device uses approved Infrared transmission spectroscopy to analyze accurately the total solids and energy content contained in the milk along with quantitative measurement of fat, protein and total carbohydrate in a single run.

The device does not use any chemicals and is small, portable and easy to use. The results can be easily transferred to a computer.

The FDA reviewed the Miris Human Milk Analyzer test through the De Novo premarket review pathway and clearance was based on comparable results obtained by analysis of 112 samples of human milk tested by the Miris analyzer and by independent methods. Both methods were equally effective at determining levels of protein, fat, and carbohydrates in the milk.

Certain conditions may limit the ability of the test to accurately determine the milk content like some medications taken by a nursing mother. FDA advises the healthcare provider to use the test results of Miris Human Milk Analyzer along with clinical parameters of the baby in formulating the nutritional plan for the infant and in informed decision making.

FDA has also put in place specific criteria called “special controls” to ensure the accuracy and reliability of the test results and to aid in the nutritional management of certain infants. These “special controls” along with general control helps maintain the specificity and accuracy of this type of tests.

Here is a short overview of how the Miris HMA - Human Milk Analyzer works.

Product page

FDA press release

Ob/Gyn Updated Facebook page

Here are the top 5 most read ultrasound posts of 2018

noreply@blogger.com ( Anjali Vyas) — Mon, 31 Dec 2018 05:48:00 +0000

With only a few hours left for the calendar year 2018 to come to an end, take a look at the top 5 most read ultrasound posts of the year as we gear up to look forward to another year of medical advances and health research.

Blob and Bagel sign on Ultrasound can be labeled as definitive for Ectopic Pregnancy

Women with the Blob and Bagel ultrasound sign should be reclassified from having ‘probable’ ectopic pregnancy (EP) to ‘definitive’ EP and should be treated as such reports the result of a large retrospective cohort study published March 11, 2018, in Journal of Ultrasound in Obstetrics and Gynecology.

Ectopic Pregnancy is still the leading cause of first-trimester maternal deaths and constitutes 4% of all pregnancy-related deaths. The incidence of ectopic is highest in women undergoing In-Vitro Fertilization (IVF) and ranges from 4% to 11% of all pregnancies.

https://obgynupdated.blogspot.com/2018/03/blob-and-bagel-sign-on-ultrasound-can.html

Novel cross-over sign in cesarean scar pregnancy helps predicts the risk of invasive placentation

First trimester ultrasound scan evaluating the relationship between the gestational sac and the endometrial line in women with cesarean scar pregnancy(CSP) helps predicts the development of abnormally invasive placenta (AIP) and consecutive intra and post-operative surgical morbidities reports the results of a retrospective case series published in the Journal of International Society of Ultrasound in Obstetrics and Gynecology.

Recent advances in prenatal imaging and increase rate of cesarean sections have led to increased diagnosis of CSP. Although, most of the patients with CSP present with severe hemorrhage or rupture uterus, that requires emergency surgical management, few advances further, evolving into AIP.

https://obgynupdated.blogspot.com/2018/02/novel-cross-over-sign-in-cesarean-scar.html

Negative sliding sign by ultrasound in repeat cesarean section predicts the presence of severe intrabdominal adhesions

A negative sliding sign by ultrasonography (USG) in patients with previous cesarean section helps alert the surgeon to expect massive intraabdominal adhesions, difficult repeat cesarean section and need of blood transfusion during surgery reports the results of a prospective observational study published ahead of print in the February issue of Journal Obstetrics and Gynecology.

Postoperative adhesion formation is quite prevalent after an abdominal or pelvic surgery and any method which can predict the existence of such adhesion could optimize the outcome of current surgery.

https://obgynupdated.blogspot.com/2018/02/negative-sliding-sign-by-ultrasound-in.html

GE Healthcare introduces its new automated breast ultrasound for dense breast

There could not have been a more appropriate time for the launch of GE Healthcare new Invenia Automated Breast Ultrasound (ABUS) 2.0 than October, which is celebrated as breast cancer awareness month. The Invenia ABUS is the only FDA approved 3D ultrasound system for supplemental screening for breast cancer along with mammography.

In conjunction with mammography, it increases the chances of cancer detection in the dense breast by 55%. All breasts are not the same, the density of breast is determined by a proportion of fat and breast tissue—when the percentage of breast tissue exceeds that of fat, breasts are labeled as being dense.

https://obgynupdated.blogspot.com/2018/10/ge-healthcare-introduces-its-new.html

A practical guide to count ovarian antral follicles by ultrasound

A consensus opinion highlighting the main techniques of ovarian antral follicle count (AFC), and providing recommendations for future research is published in the special issue on Reproductive Medicine of the journal Ultrasound in Obstetrics and Gynecology.

The consensus makes several recommendations for varied methods used in counting the antral follicles, but no single method is superior over others and the choice should make the best use of resources available in a setting.

https://obgynupdated.blogspot.com/2018/02/a-practical-guide-to-count-ovarian.html

Here are the top 10 most read posts of 2018

noreply@blogger.com ( Anjali Vyas) — Mon, 31 Dec 2018 04:52:00 +0000

With only a few hours left for the calendar year 2018 to come to an end, take a look at the top 10 most read posts of the year as we gear up to look forward to another year of medical advances and health research.

ACOG guidance on prevention of surgical-site infection in gynecologic surgery

Surgical site infections (SSIs) after gynecological surgery is a significant cause of postoperative morbidity leading to repeated hospital visits. These infections also incur heavy social and economic burden on patients and the healthcare system.

The recent ACOG practice bulletin is published in the June issue of Journal of Obstetrics and Gynecology and replaces Practice Bulletin Number 104, May 2009, and Committee Opinion Number 571, September 2013.

https://obgynupdated.blogspot.com/2018/06/acog-guidance-on-prevention-of-surgical.html

New approach to ovarian cystectomy: Transvaginal natural orifice transluminal endoscopic surgery

Natural orifice transluminal endoscopic surgery (NOTES) is a challenging minimally invasive procedure where ‘scarless’ abdominal surgeries are performed through an endoscope inserted through a natural orifice (mouth, anus, vagina, and urethra) and is considered as a less invasive approach to laparoscopic surgeries.

NOTES is considered a logical next step in the evolution of minimally invasive surgery, and the first NOTES procedure in humans is often considered to be a transgastric appendectomy performed in India in 2006 which was presented but not reported in manuscript form.

https://obgynupdated.blogspot.com/2018/01/new-approach-to-ovarian-cystectomy.html

Blob and Bagel sign on Ultrasound can be labeled as definitive for Ectopic Pregnancy

https://obgynupdated.blogspot.com/2018/03/blob-and-bagel-sign-on-ultrasound-can.html

Novel cross-over sign in cesarean scar pregnancy helps predicts the risk of invasive placentation

https://obgynupdated.blogspot.com/2018/02/novel-cross-over-sign-in-cesarean-scar.html

Negative sliding sign by ultrasound in repeat cesarean section predicts the presence of severe intrabdominal adhesions

Postoperative adhesion formation is quite prevalent after an abdominal or pelvic surgery and any method which can predict the existence of such adhesion could optimize the outcome of current surgery.

https://obgynupdated.blogspot.com/2018/02/negative-sliding-sign-by-ultrasound-in.html

GE Healthcare introduces its new automated breast ultrasound for dense breast

https://obgynupdated.blogspot.com/2018/10/ge-healthcare-introduces-its-new.html

A practical guide to count ovarian antral follicles by ultrasound

https://obgynupdated.blogspot.com/2018/02/a-practical-guide-to-count-ovarian.html

ACOG update: Letrozole is the first line therapy for ovulation induction in PCOS

The American College of Obstetricians and Gynecologists (ACOG) now recommends Letrozole (aromatase inhibitor) as the first-line treatment for ovulation induction in women with Polycystic Ovarian Syndrome (PCOS) due to data demonstrating increased ovulation rates, clinical pregnancy rates and live-birth rate vs clomiphene citrate. The guidelines are published as Practice Bulletin No. 194 in the June issue of Journal Obstetrics and Gynecology.

This replaces the Practice Bulletin Number 108, published October 2009, which recommends letrozole as first-line therapy for ovulation induction only in women with PCOS and a BMI greater than 30.

https://obgynupdated.blogspot.com/2018/05/acog-update-letrozole-is-first-line-for.html

Sonographically measured fetal head circumference ≥35 cm at term increases the odds of cesarean delivery

Sonographically measured fetal head circumference ≥35 cm, within a week of delivery increases the odds of unplanned cesarean section by 75% report the results of multicenter observational study accepted for publication in American Journal of Obstetrics and Gynecology.

Currently, In the US, one in every third baby is born by cesarean section and the high rate is a cause of concern for the healthcare industry.

https://obgynupdated.blogspot.com/2018/01/sonographically-measured-fetal-head.html

FDA approves a bedside test for assessing the risk of spontaneous preterm birth

QIAGEN won FDA approval for marketing its Novel PartoSure® point of care test for estimating the risk of spontaneous preterm birth in patients who present with symptoms of preterm labor. PartoSure represents a breakthrough in research and development of diagnostic tests for preterm birth.

Predicting preterm birth is a diagnostic challenge and nearly 85% of patients admitted to the hospital for threatened preterm labor (PTL) do not deliver within the next 7 days, resulting in unnecessary interventions.

https://obgynupdated.blogspot.com/2018/04/fda-approves-bedside-test-for-assessing.html

"Does 4 cm dilation constitute active labor?" interview with Dr. Emanuel A. Friedman

noreply@blogger.com ( Anjali Vyas) — Thu, 27 Dec 2018 23:44:00 +0000

Emanuel A. Friedman M.D., of Columbia University, introduced the labor curve, commonly known as “Friedman’s Curve ” to depict the average amount of time it took for a labor patient to dilate each cm. Published nearly 60 years ago, the curve is still followed by a majority healthcare providers to define normal labor.

In 2012, when the National Institute of Child Health and Human Development (NICHD), the Society for Maternal and Fetal Medicine (SMFM), and ACOG held a workshop aimed at “preventing the first Cesarean.” In the workshop, it was discussed that many cesarean sections are simply performed because many women are wrongly categorized as “ failure to progress” based on Friedman’s Curve.

In 2014, ACOG and SMFM issued a consensus statement “Safe Prevention of the PrimaryCesarean Delivery ” to bring down the rising cesarean section rates. The statement redefined normal and abnormal labor and stated that Friedman’s Curve should no longer be used as the basis for modern labor management (ACOG 2014).

A critical study published by Zhang et al. formed the basis of the new guidelines. The study was based on data from the Consortium on Safe Labor and looked at labor records of 62,000 women from 19 hospitals across the U.S. The researchers concluded that “ failure to progress” should be diagnosed at 6 cm and not 4 cm as stated earlier.

ACOG also reaffirmed this statement in 2017 and again in 2018 ACOG Committee Opinion No.766: Approaches to Limit Intervention During Labor and Birth.

Here is an interview with Emanuel A. Friedman about definitions of active and in active labor. He opines that “Woman describes her own labor curve, it is irrelevant to designate a particular point in labor as a demarcation between active and in active labor.”

World’s First FDA cleared blood pressure smartwatch is available to order

noreply@blogger.com ( Anjali Vyas) — Thu, 20 Dec 2018 23:36:00 +0000

Omron, the household name in blood pressure monitors is about to release the world’s first FDA cleared, medical grade, wearable blood pressure monitor in the form of a smartwatch. Named as HeartGuide, it delivers powerful technology that streamlines the blood pressure monitoring for millions with hypertension.

In combination with the companion app Heartadvisor, the watch can proactively monitor heart rate and overtime track trends with a color-coded display that makes interpretations easier. The real-time heart monitoring generates an algorithm based on a person's daily activity data and can send daily actionable reminders. The app further compares the readings to current American Heart Association/American College of Cardiology guidelines and share data with the healthcare provider.

The watch itself is equipped with a flexible, synthetic band that inflates to measure the blood pressure via oscillometry without the tightening and uncomfortable feeling associated with blood pressure cuffs. It is necessarily a full-size blood pressure monitor that has been shrunk to the size of a wristwatch.

For measuring the B.P., the hand is placed over the heart, and tapping the touchscreen of the watch activates the band. The band starts inflating and displays the B.P. reading in 30 sec. The display is color-coded–green if it is within a normal range and yellow/red if high.

It can be programmed to take blood pressure reading during sleep– a particularly helpful feature as blood pressure readings are most accurate while we sleep.

The Heartguide can also track the heart rate, daily activity, calories burned, and patterns and quality of sleep. Over time if the physical activity is short of daily routine, a reminder is sent.

The watch comes with a 1 Lithium-ion polymer rechargeable battery, that can last up to 48 hours after being fully charged. The battery lasts for 500 cycles when B.P. is measured eight times/day.

Heart conditions are widespread with nearly 40 million people in the US whose blood pressure is uncontrolled. The Heartguide will change the way heart health is monitored and will be a crucial player in support of Omron mission “Going for Zero mission” to eliminate heart attack and stroke.

The Heartguide will be available at retail on January 9, 2019. The device is currently available for preorder for $499.

Omron has a few heart monitoring devices in their pipeline, such as a blood pressure monitor and ECG combo device intended for use in the home.

Here is a promo video of Omron’s Heartguide

Product page

Ob/Gyn Updated Facebook page

Prophylactic use of aspirin can considerably bring down the incidence of preterm SGA

noreply@blogger.com ( Anjali Vyas) — Wed, 19 Dec 2018 23:51:00 +0000

Use of prophylactic aspirin in high-risk group identified by first trimester screening for preeclampsia would considerably lower the incidence of preterm and early SGA by about 20% and 40%, respectively report the results of a data analysis published July 2018 in ISUOG (International Society of Ultrasound in Obstetrics and Gynecology) journal Ultrasound in Obstetrics and Gynecology.

The researchers analyzed the data from two multicentric trials: Screening program for pre-eclampsia (SPREE) study and the Aspirin for Evidence-Based Preeclampsia Prevention trial (ASPRE). SPREE is a prospective multicenter cohort study that screened women for PE during 11-13 weeks by measuring Mean arterial pressure (MAP), Uterine artery pulsatility index (UtA‐PI), Serum placental growth factor (PlGF), and Serum pregnancy‐associated plasma protein‐A (PAPP‐A).

ASPRE trial examined the prophylactic effect of low-dose aspirin started at 11-14 weeks for prevention of PE in women at increased risk for preterm PE. The results demonstrated that aspirin reduces the incidence of early-PE by 89% and pre-term PE by 62% but does not much reduce the incidence of term PE.

The combined use of maternal factors mean arterial pressure, uterine artery pulsatility index and serum placental growth factor for the screening for preterm preeclampsia identifies a high proportion of patients who will develop small for gestational age (SGA) babies.

Screening in SPREE trial identified 46% of SGA <10th Percentile neonate born before 37 weeks and 56% of those born before 32 weeks with a screen positive rate of 12.2%. Analysis of data from ASPRE trial showed that aspirin reduced the rate of SGA <10th Percentile by 40% in babies born at or before 37 weeks and by 73% in babies born before 32 weeks.

The decrease in the incidence of SGA infants was mainly due to a substantial decrease in the incidence of PE to the amount of 90% in babies born before 32 weeks and 70% in babies born at or before 37 weeks.

Hence, the authors concluded that first-trimester screening of PE identifies a high proportion of patients with who will develop preterm-SGA as the pregnancy progresses further and the prophylactic use of aspirin can prevent that.

Here is a Video abstract of the above study

Abstract

Ob/Gyn Updated Facebook page

ASRM Video article: Technique of uterine procurement from a diseased donor for uterine transplant

noreply@blogger.com ( Anjali Vyas) — Tue, 18 Dec 2018 22:58:00 +0000

Uterine transplantation is the final frontier in the quest to provide a child-bearing option for patients with absolute uterine factor infertility. This procedure can become a promising option for the approximately 1.5 million women worldwide for whom pregnancy is not possible because of the absence of the uterus or presence of a nonfunctional uterus. Only recently we heard the news from Brazil about the first live birth following the uterine transplant from a deceased donor.

This informative and detailed video from the American Society of Reproductive Medicine (ASRM) outlines the key steps in the successful procurement of uterus from a deceased donor using illustrations and footage from a trial transplant.

The video also describes the advantage of deceased donor transplant over live donor transplant in terms of surgical time, ethical issues, larger availability and eliminating the risk of surgical complications in the live donor.

Full-Text

Ob/Gyn Updated Facebook page

RCOG updates its guidance on Pregnancy pain relief

noreply@blogger.com ( Anjali Vyas) — Mon, 17 Dec 2018 23:57:00 +0000

It is important to prescribe the correct analgesic during pregnancy to optimize the maternal and neonatal outcome. Inadequate pain-relief in pregnancy leads to anxiety and psychological strain for mother and affects her ability to provide care for her newborn–note the recent Scientific Impact Paper published December 12, 2018, in the BJOG.

The paper was developed for the Royal College of Obstetricians and Gynaecologists (RCOG) by a group of eminent doctors and researchers following the advisory issued by the Medicines and Healthcare products Regulatory Authority (MHRA) and European Medicines Agency (EMA) on the use of codeine in pregnancy because of neonatal mishap and three other fatalities in children.

The findings reflect current NHS guidance on the use of medical pain relief options in pregnancy and during breastfeeding. However, the guidance does not address the concerns for Intrapartum analgesia.

Women often need analgesic during the antenatal period for a headache, backache, and pelvic pain.

Non-pharmacological interventions like relaxation, adequate rest, heat, massage, acupuncture, posture training, physiotherapy, and exercise should be considered before starting any drugs. Notably, all drugs should be avoided during early pregnancy to prevent the teratogenic effects of drugs during the organogenesis period (4-10 weeks).

Paracetamol

Paracetamol remains the drug of choice for pain relief throughout pregnancy, although few studies have demonstrated an increased incidence of childhood asthma, behavioral problems, and a delay in gross motor and communication development in children with long‐term antenatal exposure.

NSAIDs

Studies have failed to demonstrate any clear association between congenital malformations and the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in early pregnancy.

However, there is conflicting evidence regarding the use of NSAIDs and risk of miscarriage in the first trimester. Therefore, NSAIDs be avoided during pregnancy, especially during the first trimester. They should only be used when absolutely necessary in conditions such as a migraine or ankylosing spondylitis, that too in lowest possible dose and for the shortest duration of time.

Use of NSAIDs should be avoided after 30 weeks of gestation because it can cause neonatal pulmonary hypertension and premature closure of the ductus arteriosus. NSAIDs also reduce fetal renal blood flow leading to decreased urine production and causing oligohydramnios.

Opioids (including codeine, dihydrocodeine, tramadol, and morphine)

The review says that opioid analgesic should only be used under the care of health professional in the lowest possible dose and shortest amount of time. It should be used when paracetamol has been ineffective. Limited data available does not point towards increased risk of fetal toxicity.

However, if used around the time of labor, it may lead to neonatal respiratory depression and if used for prolonged time cause neonatal withdrawal symptoms and maternal dependence.

The guidelines also highlighted the critical difference between the use of codeine and DHC during breastfeeding. If stronger analgesia is required, Dihydrocodeine (DHC) is much safer to use as compared to codeine which causes fetal toxicity.

Low doses of dihydrocodeine in combination with paracetamol can be bought over the counter but regular use of any opioid beyond 3 days should be under close medical supervision.

Gabapentin

Gabapentin is mostly used in chronic pain syndrome, and only a few studies have been done on the use of gabapentin in pregnancy. Evidence does not link the use of the drug to a particular birth defect; however, women are advised to take high doses of folic acid before conception and during the first trimester.

Gabapentin use in pregnancy after 30 weeks is very limited, and if used around the time of delivery it may lead to neonatal withdrawal syndrome.

Analgesics at the time of discharge

Majority of women who require analgesics at discharge should be prescribed paracetamol or ibuprofen. If stronger analgesics are required (cesarean delivery), women should be sent home with a limited supply of DHC. Tramadol is only given if a woman is intolerant to DHC.

Dr Dina Bisson, consultant obstetrician and gynecologist at the North Bristol NHS Trust and the lead authors of the guidance said: "It is absolutely essential that pain is managed appropriately during pregnancy and breastfeeding. Many women may develop headaches, lower back pain, and pelvic pain during pregnancy and breastfeeding, while others may have chronic conditions, where pain management is necessary.

"If pain is not adequately managed, this can have a negative impact on a woman's physical and mental wellbeing.

RCOG Scientific Impact Paper Full Text

Ob/Gyn Updated Facebook page

Higher aerobic fitness linked to longevity and better quality of life

noreply@blogger.com ( Anjali Vyas) — Sat, 15 Dec 2018 00:45:00 +0000

A new study from Cleveland clinic found that increased cardiorespiratory fitness (CRF) or aerobic fitness is associated with lower long-term all-cause mortality with no upper limit observed for the amount of exercise. Patients who demonstrated extreme CRF (≥2 SDs above the mean for age and sex) was at the lowest risk of adjusted all-cause mortality as compared to other performance groups.

People with poor aerobic fitness face the same likelihood of dying as that due to chronic diseases like diabetes, hypertension and cardiovascular disease note the researchers of this retrospective study published in the Journal of the American Medical Association Network Open.

This retrospective study recruited the largest reported cohort of 122 007 patients between Jan. 1, 1991, and Dec. 31, 2014, who underwent Exercise treadmill testing (ETT) at a tertiary care center. ETT eliminates the bias introduced due to self-reporting and is the most widely used method to measure the CRF.

Demographics and other co-morbidities were noted at the time of undergoing specified stress test under the supervision of exercise physiologist. Patients were classified into performance group by age- and sex-associated cutoffs as follows: elite (≥97.7th percentile), high (75th-97.6th percentile), above average (50th-74th percentile), below average (25th-49th percentile), and low (<25th percentile).

The mean age was 53.4years, and about 60% were male. As the performance level increased, the associated co-morbidities decreased except for hyperlipidemia (present in 30% of elite performers).

After multivariate analysis, it was seen that at any given point of time, patients in the elite group were 80% less likely to die as compared to patients with low CRF (elite vs. low: adjusted HR, 0.20; 95% CI, 0.16-0.24; P < .001). The survival benefit was more evident in older patients (70 and more) and those with hypertension. Long-term survival was adjusted for a patient’s age, sex, height, weight, BMI, medications, and comorbidities.

Hypertensive patients in the elite group were 30% less likely to suffer mortality as compared to those in the high-performance group (75th-97.6th percentile).

Patients with lowest aerobic fitness (<25th percentile) faced risks that were comparable or more than patients with chronic disease like CVD (24% more), diabetes (40% more) and smoking (40% more).

These findings highlight the importance of aerobic fitness concerning prolonging life and improving the quality of life. This study reinforces the results of previous studies that have demonstrated the benefits of achieving CRF.

“Aerobic fitness is something that most patients can control. And we found in our study there is no limit to how much exercise is too much,” said Wael Jaber, M.D., Cleveland Clinic cardiologist and senior author of the study in a news release. “Everyone should be encouraged to achieve and maintain high fitness levels.”

It also stresses the importance of continued high-level physical activity in older adults and the benefits of maintaining the highest aerobic fitness. Some recent studies have demonstrated an association between extreme high level of exercise and an increased incidence of atrial fibrillation, coronary artery calcification, myocardial fibrosis, and aortic dilation. However, it is not clear whether these findings are a simple physiological adaptation or because of cardiovascular pathology.

“We were particularly interested in the relationship between extremely high fitness and mortality,” said Kyle Mandsager, M.D., an electrophysiology fellow at Cleveland Clinic and the lead author of the study. “This relationship has never been looked at using objectively measured fitness, and on such a large scale.”

The authors conclude, “Cardiorespiratory fitness is a modifiable indicator of long-term mortality, and health care professionals should encourage patients to achieve and maintain high levels of fitness.”

Full text

Cleveland clinic news release

Ob/Gyn Updated Facebook page

Menopausal transition period is a "critical window" for cardiovascular prevention in women

noreply@blogger.com ( Anjali Vyas) — Wed, 12 Dec 2018 21:33:00 +0000

A healthy lifestyle during the perimenopausal and menopausal years reduces the risk of cardiovascular events in later life report the result of a prospective, cohort study published in in the December 4 issue the Journal of the American Heart Association.

The study is a secondary analysis of data from the ongoing, multicentric, multiethnic, prospective Study of Women's Health Across the Nation (SWAN) initiated in 1996 to know more about transition across menopause. The researchers looked at data from 1143 women to create a composite 10-year average Healthy Lifestyle Score (HLS) involving smoking, diet quality, and physical activity. All three are modifiable behavioral risk factors for CVD and earlier studies have shown an inverse association between healthy lifestyle and various CV outcomes.

The study participants were followed for an average of 15 years with the last follow-up in the year 2015-2016. Carotid ultrasound scans were performed after 14 years to measure the markers of subclinical atherosclerosis which include common carotid artery intima‐media thickness (CCA‐IMT), adventitial diameter (CCA‐AD), and carotid plaque.

Information about the diet was collected at baseline, visit 5, and visit 9 using a modified version of the Block Food Frequency Questionnaire (FFQ) and the amount was quantified using the Alternate Healthy Eating Index (AHEI).

To assess whether the recommended physical activity (≥150 minutes/week of moderate-intensity physical activity) is met or not, the participants were asked to fill the sports and exercise questions on the Kaiser Physical Activity Survey.

Data on smoking were collected using the standardized questions from the American Thoracic Association.

The HLS was calculated based on the sum of individual scores on all the three parameters at baseline, visit 5 and visit 9 and averaged to get the final score. Other covariates included in the study at baseline were age, race/ethnicity, education, financial status, marital status, depression, self-reported health status, and menopausal status.

Physiological risk factors, including BMI, high blood pressure, impaired fasting glucose, serum triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, use of antilipidemic medications, and use of antihypertensive medications were adjusted in a separate model.

The association between the individual component of HLS and the three markers of subclinical atherosclerosis were also looked at.

At 10 years follow-up, average HLS was found to be inversely and statistically significantly associated with CCA-IMT and CCA-AD — an association that persisted, even after "extensive" adjustment for confounders (P = .0031) and physiological risk factors (P < .001 for both CCA-IMT and CCA-AD).

Compared with participants with the lowest range of HLS, those with highest HLS had a 0.024 mm smaller CCA-IMT and a 0.16 mm smaller CCA-AD.

After adjusting for various physiological risk factors, the researchers did not find a statistically significant association between carotid plaque and average HLS.

Analyzing individual component of HLS, smoking conferred the highest risk for a CV event and those who never smoked had a 0.047 mm smaller CCA-IMT, a 0.24 mm smaller CCA-AD, and 49% lower odds of having a higher carotid plaque index.

The investigators message for the physicians “the menopausal transition represents a crucial, yet understudied, window of increased cardiovascular risk in women. For the prevention of future cardiovascular disease among women undergoing the menopausal transition, the physician should focus on modifiable health behaviors including smoking, diet, and physical activity."

Full text

Ob/Gyn Updated Facebook page

ASRM Video article: Hysteroscopic removal of IUD in pregnancy

noreply@blogger.com ( Anjali Vyas) — Wed, 12 Dec 2018 00:22:00 +0000

The use of Intrauterine Devices (IUD) has increased in recent years. Used correctly, the failure rate for IUD is less than 1%. If a patient gets pregnant with IUD in place, the risk of adverse outcomes like spontaneous abortion and preterm birth increases many-fold.

WHO advises removal of IUD at the earliest gestational age possible if strings are visible on vaginal examination. If strings are not visible there are 3 ways to manage a case of IUD with pregnancy:

Expectant management

Removal with a grasper under ultrasound guidance

Removal under hysteroscopic visualization

Here is a recent video-article published in December issue of Journal Fertility and Sterility, showing step by step procedure of hysteroscopic removal of IUD in 4 patients. In all four cases, the strings were not visible during a vaginal examination. After removal of IUD, all patients had uneventful live term delivery.

All patients were informed about the risk of the procedure, although negligible–– including rupture of gestation sac and pregnancy loss, consent obtained, viability and location of IUD confirmed by pre-op ultrasound and prophylactic antibiotics given. The actual procedure includes:

Vaginoscopic hysteroscopy

IUD localization with or without imaging guidance

Removal of the IUD with the help of hysteroscopic grasper

The key is to use slender hysteroscope and use the minimal amount of distention media. The method is safe with minimum procedure-related complications and > 90% ongoing pregnancy rate.

Here is the American Society for Reproductive Medicine (ASRM) video showing step by step procedure of hysteroscopic removal of IUD in 4 patients.

Full Text

Ob/Gyn Updated Facebook page

Hologic launches multipurpose Omni-Hysteroscope

noreply@blogger.com ( Anjali Vyas) — Mon, 10 Dec 2018 21:30:00 +0000

Hologic announced the launch of its FDA cleared, innovative 3-in-1 Omni™ Hysteroscope equipped with advanced visualization capabilities to streamline the diagnostic and therapeutic procedures.

The scope comes with 3 interchangeable sheaths which eliminate the physician need to change the scope between diagnostic and treatment procedures. Additionally, the scope is armed with Premium MyoSure optics to ensure clarity and quality visualization throughout the procedure.

The patients experience less pain and discomfort because the scope can be easily inserted because of thin sheaths (3.7 mm diagnostic sheath; 5 mm operative sheath; 6 mm operative sheath). It also provides long 200 mm working length to efficiently work with obese patients.

The sheaths are compatible to use with Hologic’s Fluent™ hysteroscopic fluid management system and all MyoSure® tissue removal offerings including MyoSure REACH, MyoSure XL, MyoSure LITE, and MyoSure MANUAL devices.

“Experts agree that direct visualization of the uterine cavity in women with abnormal uterine bleeding is the gold standard that allows physicians to accurately identify and collect quality samples and remove pathology – in a safer and more effective manner than blind biopsy and curettage,” said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic.

“Featuring three easily interchangeable sheaths in one scope, our new Omni scope gives physicians excellent visualization capabilities with the convenience of seeing and treating pathology in a more streamlined procedure,” he added.

Product page

Press release

Ob/Gyn Updated Facebook page

First live birth following a uterine transplant from a deceased donor

noreply@blogger.com ( Anjali Vyas) — Sun, 09 Dec 2018 04:15:00 +0000

A Brazilian woman becomes the first person to successfully give birth to a healthy baby after receiving a uterine transplant from a deceased donor. This comes after a history of previous 10 unsuccessful attempts at live birth after deceased donor transplants in the United States, the Czech Republic, and Turkey.

This is a milestone in the history of uterine transplants as it opens the path forward for achieving successful pregnancies without the need of live donor and donor surgery. The details of the case were published by the Lancet on December 4, 2018, accompanied by an editorial.

Dr. Dani Ejzenberg, PhD, the lead author and researcher from the Department of Obstetrics and Gynecology, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, said in a press release by Lancet, "The use of deceased donors could greatly broaden access to this treatment, and our results provide proof-of-concept for a new option for women with uterine infertility."

Ejzenberg and colleagues report that the 32-year old woman was born without a uterus because of congenital uterine agenesis, also called as Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, which affects 1 in 4500 women.

The woman received uterus in September 2016 after 10.5-hour surgery from a 45-year old multiparous woman who died of subarachnoid hemorrhage. After the transplant, the woman was discharged on the 8th postoperative day with immunosuppression achieved and maintained with prednisolone and thymoglobulin and continued via tacrolimus and mycophenalate mofetil (MMF) when at five months post-transplant, azathioprine replaced MMF.

The woman got her first period 37 days after transplant and after that continued to have regular cycles every 26–32 days. Pregnancy occurred following single embryo-transfer after seven months from cryopreserved blastocyst from a successful in-vitro fertilization four months before the transplant surgery.

The pregnancy progressed uneventfully and was monitored by ultrasound and Doppler flow velocity waveforms of uterine arteries, fetal umbilical, or middle cerebral arteries.

A healthy, female baby weighing 2550 g was delivered by elective cesarean section at 36 weeks on December 15, 2017. At the time of writing the article, the baby is healthy and developing normally.

The uterus was also removed at the time of cesarean section, and immunosuppressive therapy stopped.

Cesar Diaz-Garcia, MD, Nuffield Department of Women's and Reproductive Health, University of Oxford, UK, and Antonio Pellicer, MD, PhD, Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Spain, writes in an accompanying editorial, "In a context in which the scarcity of human data is still the norm, [the report] reveals a breakthrough in the field of uterus transplantation."

The first uterine transplant from a living donor took place in Sweden in 2013, followed by first live-birth after transplant in 2015. Since then, 11 more births have taken place worldwide, albeit all from live donor transplant.

However, uteri from living donors are limited because the person has to a relative of the recipient, thereby, limiting the option for women with uterine factor infertility. If uterine transplant after dead donor becomes successful, uteri will not be in short supply as people are more willing to donate organs after death than when they are alive.

The authors agree that many potential issues need to be addressed before deceased donor transplant becomes a norm. These include standardization of operative procedures, immunosuppressive therapy before and during pregnancy, criteria for rejection if it happens, and long-term outcome of the baby delivered after transplant.

Abstract

Ob/Gyn Updated Facebook page